Henry 1995.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 132, lung, gynecological, gastrointestinal, hematological malignancies, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = Hct 38%‐40% planned ESA duration = 12 weeks
Outcomes	Primary: Hct, transfusion; secondary: correction of anemia, response, QoL, safety
Notes	study number = 70332
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer generated
Allocation concealment?	Unclear risk	Medication boxes were used, but without identical appearance